Theranostic pair for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a radioactive drug and its imaging partner to find and treat kidney cancer that has spread. You get a scan first to see if the cancer absorbs the drug, and if it does, you receive the therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have advanced kidney cancer (clear cell type) that has stopped responding to standard treatments.
- Your cancer shows up on a special scan that looks for a protein called CA9.
- You are well enough to be up and about (ECOG score 0 or 1).
- Your organs (kidney, liver, bone marrow) are working well enough.
- You have not had certain cancer treatments in the last month, and you do not have serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
This trial tests a new PET/CT scan that uses a special tracer to find clear cell kidney cancer. If you are scheduled for kidney tumor removal, this scan may help your surgeon see the cancer more clearly before surgery.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
This trial tests a new drug called 177Lu-TLX250, which delivers radiation directly to kidney cancer cells. It is for people with advanced clear cell renal cell carcinoma that has returned or not responded to at least 2 prior treatments.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.